NeogenFRA:NG2 +5.08%68 Market Cap is €1,838.8 Mil as of Jul. 11, 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Neogen ranks better than 88.45% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Neogen's share price for the quarter that ended in Feb. 2026 was €9.5. Neogen's Shares Outstanding (EOP) for the quarter that ended in Feb. 2026 was 217.7 Mil. Therefore, Neogen's market cap for the quarter that ended in Feb. 2026 was €2,067.9 Mil.
Neogen's quarterly market cap
increased
from Aug. 2025 (€1,064.8 Mil) to Nov. 2025 (€1,131.1 Mil) and
increased
from Nov. 2025 (€1,131.1 Mil) to Feb. 2026 (€2,067.9 Mil).
Neogen's annual market cap
declined
from May. 2023 (€3,416.7 Mil) to May. 2024 (€2,664.4 Mil) and
declined
from May. 2024 (€2,664.4 Mil) to May. 2025 (€1,172.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neogen's Enterprise Value for Today is €2,395.0 Mil.
Neogen (FRA:NG2) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Neogen Market Cap Related Terms
Neogen Market Cap Historical Data
* Premium members only.
The historical data trend for Neogen's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs UFPT, ALMR, BFLY: Market Cap Comparison
For the Medical Devices subindustry, Neogen's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Market Cap distribution charts can be found below:
* The bar in red indicates where Neogen's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Neogen's Market Cap for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a Market Cap of €1,838.8 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neogen and its competitors. According to the industry distribution chart, Neogen ranks #100 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 11.5%.
Is Neogen's Market Cap too high?
Neogen's current Market Cap is €1,838.8 Mil. Based on the distribution chart, Neogen ranks #100 out of 866 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Market Cap compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #100 out of 866 companies for Market Cap. This places Neogen in the top 12% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 116.25, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 116.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current Market Cap is €1,838.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current Market Cap is €1,838.8 Mil. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Market Cap is €1,838.8 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
Market Cap: €1,838.8 Mil
GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
